Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.

Oncotarget - 22 Sept 2015

O'Neill Daniel, Jones Dominic, Wade Mark, Grey James, Nakjang Sirintra, Guo Wenrui, Cork David, Davies Barry R, Wedge Steve R, Robson Craig N, Gaughan Luke

Abstract excerpt

The persistence of androgen receptor (AR) signalling in castrate-resistant prostate cancer (CRPC) highlights the unmet clinical need for the development of more effective AR targeting therapies. A key mechanism of therapy-resistance is by selection of AR mutations that convert anti-androgens to agonists enabling the retention of androgenic signalling in CRPC. To improve our understanding of these receptors in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Androgen Antagonists
Share to Anilides

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Benzamides

Share to Immediate-Early Proteins

Share to Nitriles

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26267320
DOI: 10.18632/oncotarget.4347
PMCID: PMC4694883

Genes

SGK1
RASD1
TIPARP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy.PMID 26267320Read ↗

Biologic and clinical significance of androgen receptor variants in castration resistant prostate cancer.Semantic proximity Read ↗

Androgen receptor plasticity and its implications for prostate cancer therapy.Semantic proximity Read ↗

A novel small-molecule androgen receptor antagonist selective for the T878A-mutant AR in prostate cancer therapy.Semantic proximity Read ↗

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.Semantic proximity Read ↗

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate CancerSemantic proximity Read ↗

A sting in the tail: the N-terminal domain of the androgen receptor as a drug targetSemantic proximity Read ↗

The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on TherapySemantic proximity Read ↗

A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.Semantic proximity Read ↗

Constitutive activity of the androgen receptor.Semantic proximity Read ↗

Mutation of the androgen receptor causes oncogenic transformation of the prostate.Semantic proximity Read ↗

Androgen receptor gene mutation, rearrangement, polymorphism.Semantic proximity Read ↗

5β-Dihydrotestosterone reveals a mutant androgen receptor vulnerability in prostate cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.